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Abstract: Poly(trimethylene carbonate) (PTMC) has wide biomedical applications in the 1 
field of tissue engineering, due to its biocompatibility and biodegradability features. Its 2 
common manufacturing involves photo-fabrication, such as stereolithography (SLA), 3 
which allows for the fabrication of complex and controlled structures. Despite the great 4 
potential of SLA-fabricated scaffolds, very few examples of PTMC-based drug delivery 5 
systems fabricated using photo-fabrication can be found ascribed to light-triggered 6 
therapeutics instability, degradation, side reaction, binding to the macromers, etc. These 7 
concerns severely restrict the development of SLA-fabricated PTMC structures for drug 8 
delivery purposes. In this context, we propose here as proof of concept, to load a drug 9 
model (dexamethasone) into electrospun fibers of poly(lacid acid) (PLA), and then to 10 
integrate these bioactive fibers into the photo-crosslinkable resin of PTMC to produce 11 
hybrid films. Such polymer/polymer hybrids exhibit advanced properties compared to 12 
PTMC-only films, in terms of mechanical performance and drug protection from UV-13 
denaturation. We further validated that the dexamethasone preserved its biological 14 
activity even after photoreaction within the PTMC/PLA hybrid structures by investigating 15 
bone marrow mesenchymal stem cells proliferation and osteogenic differentiation. This 16 
work opens the field to drug loaded polymer/polymer composite structures obtained using 17 
photo-crosslinking for additive manufacturing processes such as stereolithography. 18 
Key words: 19 
fiber reinforced composite, poly(trimethylene carbonate), photo-crosslinking, 20 
dexamethasone, osteogenic materials. 21 
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Introduction 1 
Poly(trimethylene carbonate) (PTMC) is a biocompatible and degradable 2 
polymeric material that can be synthesized via the ring-opening reaction of 1,3-3 
trimethylene carbonate.1 Its degradation, mediated by a surface-erosion 4 
mechanism, is characterized by an extremely low level of non-enzymatic 5 
hydrolysis and by the release of non-acidic by-products, which makes PTMC an 6 
attractive material as polyester alternative for medical applications.2,3 However, 7 
PTMC is usually considered to have poor mechanical performance, which restricts 8 
its applications, in particular for tissue scaffolding. Several strategies have been 9 
developed to improve the mechanical properties of PTMC, by increasing molecular 10 
weight,4 blending with  stiffer polymers or inorganic particles,5-7 copolymerizing 11 
with ‘hard’ polymer blocks8 or crosslinking.9 Recently, Schüller-Ravoo et al 12 
synthesized three-armed PTMC methacrylate macromers that can be photo-13 
crosslinked to produce flexible and tear-resistant elastomeric materials.10 In 14 
addition, the ability to photo-initiate crosslinking permits the use of 15 
stereolithography (SLA), a common additive manufacturing technique, to build 16 
PTMC-based structures with excellent degree of precision in the control of three-17 
dimensional architectures.11-13  18 
An interesting feature of the slow surface degradation and erosion profile of PTMC 19 
based materials is that they allow good control of the release profile of drugs in 20 
presence of enzymes (such as lipases).14-16 Despite the potential of SLA-fabricated 21 
scaffolds, very few examples of PTMC drug delivery systems fabricated using 22 
photo-fabrication can be found in the literature.14 A major inconvenient of SLA, in 23 
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designing drug-loaded scaffolds, is that UV irradiation and radical generation can 1 
result in the degradation or reactivity of the drug being encapsulated, often at 2 
relatively low concentrations. Indeed, SLA requires successive layer-by-layer 3 
photoreactions of the methacrylate macromers. This intrinsically restricts the 4 
potential of SLA-fabricated scaffolds to be used as drug delivery carrier, due to 5 
radical-mediated chemical cross-reactions and due to the light sensitivity of the 6 
majority of therapeutic compounds. So far, only Vitamin B12 (as model) has been 7 
incorporated into PTMC photo-crosslinkable matrix, under the form of non-soluble 8 
micro-granules to prevent any degradation.14 In order to confer bioactive properties 9 
to SLA-fabricated PTMC scaffolds, we recently reported the incorporation of 10 
hydroxyapatite (HA) nanoparticles into the PTMC-based photo-crosslinkable 11 
resins. The composite PTMC-HA scaffolds successfully stimulated bone formation 12 
in a calvarial defect model in rabbit.11 Nevertheless, a high loading of HA particles 13 
up to 40 weight % was required to elicit beneficial osteogenic effects, which 14 
renders the resin highly viscous and difficult to process for SLA-based additive 15 
manufacturing. As alternative, we further developed composite PTMC structures 16 
with enhanced mechanical properties, by incorporating electrospun poly(lactic 17 
acid) (PLA) fibers in methacrylate-terminated PTMC macromers followed by UV 18 
crosslinking.17 The improvement in PTMC mechanical performance combined 19 
with its potential bioactive and shape memory properties18 has brought interests in 20 
designing drug delivery systems that can further enhance bioactivity, in particular 21 
osteogenicity.  22 
Dexamethasone (Dexa) is an ideal drug candidate for such applications as it is 23 
widely used in vitro and in vivo to regulate osteodifferentiation.19,20 Dexa is a 24 
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synthetic glucocorticoid with several therapeutic applications, such as anti-1 
inflammatory, immunosuppressant and decongestant.21 It also displays potent 2 
effects on the proliferation and osteogenic differentiation of mesenchymal stem 3 
cells (MSCs) in presence of β-glycerol phosphate and ascorbic acid/ascorbate,22,23 4 
with optimal concentrations ranging from 10 to 100 nM.24 Similarly, icaritin is a 5 
metabolite of the flavonoid glycoside extracted from Herba Epimedii, which was 6 
reported to enhance the differentiation and proliferation of osteoblasts.25 7 
Various systems have been developed as Dexa carriers, allowing a sustained 8 
release, such as implant dispensers,26 nanoparticles/hydrogel complexes,27 self-9 
assembled nanofibrous gels,28 electrospun fibers,29 macroporous scaffolds30 and 10 
extrusion-based structures.24 Among those, Dexa-charged nanoparticles can easily 11 
be administered but have low drug loading efficiency. It is also difficult to prevent 12 
their dispersion in the body following their administration for local treatment. 13 
Hydrogel/fiber composites are more suitable for local delivery and showed 14 
controlled release profiles, but their poor mechanical performance restricts their 15 
potential applications. Electrospun polymer nanofibers have gained significant 16 
interest for drug encapsulation, due to their ease of fabrication, high drug 17 
incorporation efficiency, large surface area and the inherent porosity of the 18 
scaffolds they form.31 However, a burst release usually occurs as a result of drug 19 
accumulation on the fiber surface and the high surface area of these materials.32,33 20 
The initial burst release can be alleviated by improving drug-polymer compatibility 21 
and drug solubility in polymer solution during electrospinning (i.e. employing 22 
surfactants, although often by compromising cytotoxicity). A sustained release can 23 
also be achieved by fabricating complex materials that encapsulate drugs in a core-24 
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shell structure, modifying fiber’s chemical properties or using drug-binding 1 
agents.34-38 However, these approaches considerably increase the complexity of the 2 
processing methodologies and require novel chemical functionalisation that may 3 
prevent regulatory approval and clinical translation. 4 
The objective of our work was to fabricate PTMC/PLA nanofiber composite 5 
systems (based on fibers with diameters in the micron range and below), allowing 6 
the control of the release of model drugs promoting osteogenic differentiation in 7 
vitro, Dexa and icaritin. PLA was selected for the fabrication of electrospun fibers 8 
since it is commercially available, biocompatible, degradable, FDA approved and 9 
significantly stiffer than PTMC (to achieve reinforcement). In addition to 10 
composite formulation, PLA has also been routinely used to modify the physical 11 
properties of degradable polymers, by copolymerizing with other monomers.39 In 12 
addition, combination with the PTMC matrix also improves the ductility of brittle 13 
PLA fibre materials17 and confers shape memory properties, as previously reported 14 
by our group.18 PLA fibers loaded with Dexa were electrospun and incorporated 15 
into a photo-cured PTMC matrix. In addition to mechanical reinforcement, our 16 
results demonstrate the preservation of the drug activity and the control of its 17 
diffusion, compared to a direct drug-loaded PTMC strategy. In order to validate 18 
this approach, the biological activity of Dexa-loaded PTMC-PLA films was 19 
assessed by investigating their osteogenic properties on human mesenchymal stem 20 
cells.  21 
The ability to generate mechanically enhanced photo-cured PTMC composites able to 22 
release active therapeutics constitutes an important progress in the use of these materials 23 
for additive manufacturing and tissue engineering applications. 24 
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 1 
Materials and methodsMaterials 2 
Poly(lactic acid) (PLA 2002D, Mw 200,000 g/mol, density 1.24 g/cm3) was obtained from 3 
Natureworks. PTMC (three-armed methacrylate-ended, Mn 10,000 g/mol) macromer was 4 
synthesized as previously reported.40 Chloroform, dimethylformamide (DMF), methanol, 5 
dichloromethane, ethyl acetate, acidic acid, tetrahydrofuran and acetonitrile (HPLC grade) 6 
were obtained from Fisher Scientific. Poly(ethylene glycol) methacrylate (average Mn 7 
360 g/mol), Dexamethasone (Dexa), 2-Hydroxy-4’-(2-hydroxyethoxy)-2-8 
methylpropiophenone (Irgacure 2959, I2959), triethylamine were purchased from Sigma-9 
Aldrich. Icaritin was obtained from Shenzhen Institutes of Advanced Technology, 10 
Chinese Academy of Sciences. Phosphate buffered saline was prepared by dissolving one 11 
tablet (Sigma-Aldrich) in 200 ml deionized water. All materials and reagents were used 12 
as received. 13 
Electrospinning and composites preparation 14 
The electrospinning was performed using an in-house-built electrospinning system. 15 
To spin PLA and icaritin/Dexa-loaded PLA fibers, a PLA solution at concentration 16 
of 9 wt% in chloroform/DMF (chloroform/DMF=3/1) was firstly prepared. For 17 
icaritin-loaded/low Dexa loading fibers, 0.50 wt% of icaritin/0.68 wt% of Dexa 18 
(with respect to PLA) was added to the PLA solution respectively. They were 19 
stirred until fully dissolved. For higher Dexa loaded fibers (2.42 wt% with respect 20 
to PLA), methanol was used to replace DMF while preparing PLA solution in order 21 
to increase the drug solubility. The ratio of chloroform/methanol was set at 3/1. 22 
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The PLA or PLA-Dexa solution was supplied through a PTFE tube at 1.0 mL/h to 1 
the electrospinning spinneret. The spinning was carried out at voltage of 18-20 kV 2 
and a distance of 15 cm. Random fiber mats were collected on a grounded 3 
aluminium foil sheet. Finally four different fiber mats (neat PLA fiber mats (PLA 4 
0), PLA-icaritin fiber mats, PLA-low Dexa fiber mats (PLA 1) and PLA-high Dexa 5 
fiber mats (PLA 2)) were obtained and they were evaporated in vacuum desiccator 6 
for 48 h to remove residual solvent. 7 
A hot-press was used to incorporate electrospun fibers into the PTMC matrix. To 8 
perform hot-pressing, PTMC macromer was first dissolved in dichloromethane at 9 
50 wt% concentration together with 0.67 wt% of Irgacure 2959 (I2959, low 10 
cytotoxicity photoinitiator,41 with respect to PTMC). After dissolution, the 11 
PTMC/dichloromethane solution was transferred into a vacuum desiccator for 48 12 
h to remove the dichloromethane. The dried PTMC/I2959 mixture was then ready 13 
to use for hot-pressing (Collin P300E). 40 mg of PLA fibers mat with a size of 14 
50×50×0.08 mm, called PLA 0, PLA 1 and PLA 2, for PLA loaded with 0, 0.68 15 
and 2.42 wt% of Dexa respectively, was placed in a 60×60×0.15 mm mould, which 16 
was then transferred into the hot-press. 160 mg PTMC macromer (containing I2959) 17 
was placed on top of the fiber mat. Fibers and PTMC were pre-warmed at 60˚C for 18 
5 min and then pressed under 25 bar pressure. A compressed film of 0.06 mm 19 
thickness was removed from the mould after cooling to room temperature. This 20 
was followed by exposing the resulting composite films under UV irradiation 21 
(Omnicure 1500) for 100 s at 15 mW/cm2 to cure the PTMC macromer. The 22 
composite films were then stored in a nitrogen box prior to further characterisation 23 
and experiments. For comparison, PTMC samples without fibers were prepared by 24 
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casting PTMC/I2959 dichloromethane solution in 50×5×1 mm mould followed by 1 
evaporating solvent. PTMC was UV-cured using the same parameters as described 2 
above. Four different groups of samples were prepared, named PTMC (for PTMC 3 
without any integrated PLA fiber), PTMC/PLA 0, PTMC/PLA 1 and PTMC/PLA 4 
2 for composite PTMC matrix integrating PLA fibers loaded with 0, 0.68 and 2.42 5 
wt% of Dexa respectively. 6 
Electrospun fiber and PTMC/fiber composites characterization 7 
The morphology of electrospun fibers and PTMC/PLA fiber composites were 8 
characterized using scanning electron microscopy (SEM, FEI Inspect F). All 9 
samples were mounted onto SEM specimen stubs and sputter-coated with a thin 10 
gold layer for contrast. To investigate PTMC infiltration and PTMC-fiber 11 
interaction, composites samples were cold-fractured in liquid nitrogen and the 12 
fracture surface was characterized using SEM. Thermal properties of electrospun 13 
fibers were measured using differential scanning calorimetry (DSC, PerkinElmer 14 
DSC 4000). Samples were first equilibrated at 25˚C and then ramped to 180˚C at 15 
10 ˚C/min. Glass transition temperature (Tg) was determined by the mid-point of 16 
glass transition. The crystallinity of PLA was calculated by, 17 
𝑋𝑐 =
∆𝐻𝑚
∆𝐻𝑟𝑒𝑓
× 100% 18 
where Xc is the crystallinity, ΔHm is the experimental heat of fusion at melting point 19 
determined by DSC, ΔHref is the theoretical heat of fusion of fully crystalline PLA 20 
(93 J/g).42 Tensile tests of electrospun fiber mat and PTMC/PLA fiber composites 21 
were performed using dynamic mechanical test (DMA, TA Q800) in controlled 22 
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force mode. Samples were cut into 20×5×0.06 mm rectangular strips before being 1 
mounted into the clamps. A preload force of 0.05 N was applied and specimen 2 
were stretched at 0.1 N/min rate until failure at room temperature. The Young’s 3 
modulus was derived from the slope of stress-strain curve at low strain (2 %) and 4 
three tests were performed on each sample. 5 
Gel permeation chromatography analyses 6 
Gel permeation chromatography (GPC) was employed to investigate the possible 7 
coupling between Dexa and the methacrylate-ended PTMC macromers, in the 8 
presence of photoinitiator, during UV curing. We examined the refractive index 9 
(RI) signal of methacrylate and Dexa before and after UV curing. Instead of 10 
PTMC-methacrylate, a model of macromer PEG-methacrylate was used and 11 
dissolved in tetrahydrofuran (THF) at concentration of 2.0 mg/mL. Dexa and I2959 12 
were added at 0.20 mg/mL and 0.17 mg/mL, respectively. The solution was 13 
degassed with nitrogen for 30 min and divided into two portions, one of which was 14 
UV treated at 15 mW/cm2 for 100 s and the other not. For reference, THF solutions 15 
of Dexa and I2959 were also tested separately to identify their signals. The GPC 16 
tests were performed using Agilent Technologies 1260 infinity equipped with UV 17 
detector at 308 nm wavelength. Tetrahydrofuran (with 2.0 vol% triethylamine) was 18 
used as the eluent at a flow rate of 1.0 mL/min. 19 
In vitro measurement of icaritin and Dexamethasone release 20 
The amount of icaritin released in phosphate-buffered saline (PBS) was calculated by 21 
measuring the remaining icaritin in samples using high performance liquid 22 
chromatography (HPLC, Waters e2695) equipped with UV detector and a Kinetex 23 
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column (Phenomenex, C18, 100 Å, 5 µm, 150×4.6 mm). The mobile phase was 25/75 1 
(v/v) water/acetonitrile, eluted at 1.0 mL/min, with water phase adjusted to pH 4 by 2 
adding 0.5 vol% of acetic acid and 0.3 vol% triethylamine. The test was performed at 360 3 
nm UV adsorption wavelength with 20 µL injection. Electrospun PLA fiber mats were 4 
cut into 10×10 mm specimens and immersed in 10 mL PBS. At different time intervals, 5 
specimens were removed from PBS, rinsed with deionised water and extracted using ethyl 6 
acetate. The extractant (ethyl acetate) was evaporated and re-dissolved in methanol and 7 
analysed using HPLC (n=3 per group). Dexa concentration in PBS was analysed using 8 
the same HPLC equipment described above. The mobile phase was 50/50 (v/v) 9 
acetonitrile/PBS, eluted at 1.0 mL/min. The test was performed at 256 nm UV adsorption 10 
wavelength with 50 µL injection for each solution. To evaluate the Dexa elution from 11 
electrospun PLA fibers and PTMC/PLA fiber composites, 15×15 mm specimens were cut 12 
out from each sample and immersed in 3 mL PBS into incubator at 37˚C for a period of 13 
five weeks. At different time points, each specimen was removed from the media and 14 
transferred into 3 mL fresh PBS. The recovered media was then analysed using HPLC 15 
(n=3 per group).  16 
   17 
Cell culture and differentiation assays 18 
PTMC/PLA fiber composite films (PTMC/PLA 0, 1 and 2) were punched into discs 19 
with diameter of around 6.0 mm (each disk weighs around 1.5 mg). The disks were 20 
then placed in 96-well plate and sterilized in ethanol 70% for 10 min. 21 
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Human bone marrow mesenchymal stem cells (hBMSCs) were isolated from 1 
vertebral body bone marrow aspirates and obtained from donors undergoing spinal 2 
fusion with informed written consent and full ethical approval (from Kantonal 3 
Ethikkomission Bern 126/03). hBMSCs of two donors were expanded individually 4 
and seeded separately, at passage 3, onto the films at a density of 20,000 cells/cm2. 5 
In order to investigate the biological activity of Dexamethasone released from the 6 
composite structures (PTMC/PLA 0, 1 and 2), the cells were cultivated in 7 
osteogenic media depleted of any Dexamethasone (called "OM –") based on basic 8 
low glucose DMEM (GIBCO) supplemented with 10 % serum (SeraPlus), 1 % 9 
penicillin/streptomycin (GIBCO), 50 µg/mL ascorbic acid and 5 mM glycerol-2-10 
phosphate (all from Sigma-Aldrich). The osteogenic differentiation of hBMSCs in 11 
the described groups were compared to cells seeded on PTMC/PLA 0, cultivated 12 
under non-osteogenic condition (negative control in basal medium, called "BM", 13 
based on basic low glucose DMEM supplemented with 10 % serum and 1 % 14 
penicillin/streptomycin) and complete osteogenic medium (positive control, called 15 
"OM +" similar to "OM – " composition but supplemented with 10 nM 16 
Dexamethasone, from Sigma-Aldrich). After seeding, the 96-well plates were 17 
filled with 200 µL of the different medium and were changed three times a week 18 
for the 28 days of the osteogenic experiment. For all the in vitro investigation, 19 
control surfaces based on tissue culture polystyrene (TCPS) was used (96 well plate 20 
TPP, Trasadingen, Switzerland).  21 
The cytocompatibility of the different composite films and the cell proliferation 22 
kinetic was evaluated using CellTiter Blue assay (Promega, Dübendorf, 23 
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Switzerland) at 2, 6, 14, 21 and 28 days post-seeding (n=5 per group), following 1 
the supplier's recommendation. The resulting fluorescence intensity was read with 2 
a multi-plate reader (Viktor3, 1420 Multilabel Count, Perkin-Elmer) and values 3 
were corrected using cell-free condition. 4 
For DNA quantification, samples were first incubated in lysis buffer made of Triton 5 
X-100 at 0.1 % in 10 mM of Tris-HCl, pH=7.4 (all from Sigma-Aldrich) and 6 
followed by one freezing-thawing cycle. Then, DNA amount was estimated using 7 
fluorescent CyQuant® GR Dye assay, according to the supplier's recommendation 8 
(Invitrogen), (n=3 per group). Alkaline phosphatase activity (ALP) from the cell-9 
lysis solution was determined using colorimetric quantification. Briefly, samples 10 
along with a set of standard solutions (p-nitrophenol of concentrations from 0 to 11 
1,000 µM) were incubated with alkaline buffer solution (2-amino-2-12 
methylpropanol 1.5 M pH=10.3, from Sigma-Aldrich) and then ALP substrate 13 
buffer was added (phosphatase substrate dissolved in diethanolamine buffer at 1 M 14 
in 0.5 mM MgCl2 adjusted pH=9.8). After mixing, and heating (at 37 oC for exactly 15 
15 min), a solution of NaOH at 0.1 M was added to each tube in order to stop the 16 
reaction. Then, the intensity of p-nitrophenol formation was monitored at 405 nm. 17 
The total ALP contents were expressed as enzyme activity units in nmol/min (n=3 18 
per group), as a function of total DNA (ng) per well measured using CyQuant® 19 
assay. ALP staining was performed after washing the cell monolayers with PBS (3 20 
times), fixation (with ice cold ethanol 90 % for 4 min.), washing with deionised 21 
(DI) water and lately, staining with Fast Blue dye solution for 1 h wrapped in tin 22 
foil (Naphthol AS-MX, according to Sigma's recommendation). After incubation, 23 
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samples were washed 3 times with DI water and imaged by light microscopy 1 
(MacrofluoTM from Leica). 2 
The occurrence of mineralization was detected using Alizarin Red Staining (ARS, 3 
Sigma-Aldrich), with TCPS used as control films. The cell monolayer was washed 4 
with PBS, fixed with formaldehyde 4 % and further washed with DI water. Then, 5 
40 mM ARS solution at pH=4.2 was added to each well for 1 h and thoroughly 6 
washed with DI water for 5 days. Finally, samples were imaged by light 7 
microscopy (MacrofluoTM from Leica) and a quantification of the ARS was 8 
performed by acid extraction thereafter. Briefly, acetic acid (at 10 %) was added to 9 
each well for 30 min, and the loosely attached monolayer of cells was transferred 10 
to Eppendorf tubes and heated up to 85 oC for 10 min, then placed on ice for 5 min. 11 
After centrifugation at 20,000 g for 15 min, ammonium hydroxide was added to 12 
the supernatant (final pH of 4.1-4.5) and absorbance was recorded at 405 nm and 13 
compared to ARS standard solutions ranged from 0 up to 2,000 µM (n=3 per group) 14 
(For all the mentioned assays, background values obtained from cell-free condition 15 
are subtracted to the final values).  16 
SEM analyses required the fixation of the samples overnight in buffered 17 
paraformaldehyde at 4 %, the dehydration with gradual concentration of ethanol up to 18 
100 % followed by immersion in hexamethyldisilazane (Sigma-Aldrich). After complete 19 
drying, the samples were sputter-coated with C and investigated using a Hitachi S4700 20 
FESEM instrument. In order to validate the presence of CaP mineralization by hBMSCs 21 
triggered by the release of Dexa from PTMC/PLA films, we carried out energy dispersive 22 
X-ray analysis (EDX, Oxford Instruments, UK), following C coating.  23 
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Statistical analyses 1 
Statistical analysis of data was performed using Prism software (GraphPad Software, La 2 
Jolla, CA, USA). We assumed normal distribution of data. One-way ANOVA with 3 
Tukey’s multiple comparison test was applied to detect significant differences between 4 
experimental groups (with p < 0.05). Data presented are means ± standard deviation (SD) 5 
unless stated otherwise. 6 
 7 
Results and discussion 8 
Physical properties of the PTMC / PLA hybrid structures 9 
The morphologies of electrospun fibers (with and without Dexa) were 10 
characterized using SEM (Figure 1A). The incorporation of Dexa into PLA 11 
produced more uniform and smaller fiber dimensions, with an average diameter for 12 
PLA fibers decreasing from 1.23 ± 0.47 µm (PLA 0) to 0.39 ± 0.14 µm and 0.74 ± 13 
0.15 µm for PLA 1 and PLA 2, respectively (Figure 1B). Some heterogeneity (e.g. 14 
beads) was observed on fibers with 0.68 wt% Dexa, which is ascribed to the 15 
decreased viscosity of the spinning solution. However, no beads were observed on 16 
fibers with 2.42 wt% Dexa, which displayed smooth surfaces. The difference was 17 
attributed to the increased solubility of Dexa in methanol (used at higher Dexa 18 
concentrations) compared to DMF. Moreover, the formation of larger fibers using 19 
methanol (fibers with high drug loading) compared to those formed in DMF (fibers 20 
with low drug loading) is explained by the faster evaporation rate of methanol 21 
17 
 
compared to DMF, which resulted in quicker solidification of the fluid jet and 1 
reduced fiber stretching. 2 
The thermal properties of electrospun fibers were characterized next, using DSC 3 
(Figure 2A and B). A melting point (Tm) at 154˚C is measured for all samples 4 
except for PLA 2 (153˚C). The glass transition temperature (Tg) of bulk PLA 5 
(63.9˚C) was decreased after electrospinning (PLA 0, 60.0˚C) and further 6 
decreased to 59.2˚C (PLA 1) and 59.0˚C (PLA 2) respectively upon incorporation 7 
of Dexa. The decrease in Tg after electrospinning is caused by the inner stress 8 
retained within fibers as a result of jet stretching, which makes molecules become 9 
mobile at lower temperatures.32 Small molecules, such as Dexa, are considered to 10 
act as plasticizer and further decreased the Tg of PLA, although this transition 11 
remained significantly higher than body temperature. Cold crystallization is 12 
observed on all electrospun PLA fibers’ thermograms. The cold crystallization 13 
peak becomes sharper and cold crystallization temperature (Tcc) is shifted to lower 14 
temperatures (from 95.4˚C to 87.9˚C) after incorporating 2.42 wt% Dexa. The 15 
crystallinity of bulk PLA is decreased from 34.4 % to 3.40 % after electrospinning 16 
and further decreased to 2.10 % after adding 0.68 wt% Dexa. However, the 17 
crystallinity is increased slightly to 5.70 % when using methanol instead of DMF. 18 
The changes in PLA crystallinity are considered to affect the mechanical properties 19 
of fibers which were further studied via tensile tests. 20 
We next investigated the formation of PTMC/PLA fiber composites. In our 21 
previous report,17,18 PTMC/PLA fiber composites were prepared by impregnating 22 
PTMC/propylene carbonate solution into electrospun PLA fiber mat, followed by 23 
UV-crosslink and solvent extraction (for removing propylene carbonate). Based on 24 
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the established method, we first integrated icaritin-loaded PLA fibres into PTMC 1 
and monitored its in vitro release, via HPLC. A representative chromatogram of 2 
direct icaritin injection is shown in Figure 3A; an icaritin peak at 3.5 min elution 3 
time was observed. However, in the following in vitro release assays, no icaritin 4 
release was observed from PTMC/PLA fibre composites in contrast to the slow-5 
release of icaritin observed from PLA fibres alone. To verify whether icaritin was 6 
physically trapped in PTMC or lost during composite preparation procedure, a 7 
series of tests were performed. Firstly, the PTMC/icaritin-loaded fibre composites 8 
were incubated in a good solvent, THF, for 24 h. The supernatant was retrieved 9 
and analysed using HPLC; no icaritin was detected (a representative chromatogram 10 
of supernatant is shown in Figure 3B, in which the icaritin peak disappeared). 11 
Secondly, PTMC/PLA fibre composites were incubated in icaritin/THF solution at 12 
known-concentration for 24 h. No decrease in icaritin concentration was observed, 13 
implying that icaritin does not simply remain trapped in these scaffolds. Thirdly, 14 
icaritin was incorporated into PTMC by directly dissolving in PTMC/propylene 15 
carbonate solutions. The icaritin-loaded PTMC was extracted by THF, but still no 16 
icaritin was observed by HPLC. Hence our data suggested that icaritin was not 17 
physically trapped in the composites, but was somehow degraded or trapped during 18 
the photopolymerisation process. We further analysed the extracted fractions that 19 
were used for the removal of propylene carbonate after polymerisation. No icaritin 20 
was detected in these solutions either, indicating that no icaritin was lost during the 21 
composite preparation procedure either. We therefore proposed that icaritin was 22 
extracted from electrospun fibres into the PTMC/propylene carbonate phase and 23 
reacted with methacrylate-ended PTMC macromers during the UV-crosslinking of 24 
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the matrix. Hot pressing, a solvent-free composite preparation method, was 1 
therefore used for the rest of our work. Indeed, after icaritin-loaded electrospun 2 
PLA fibres were incorporated into PTMC, icaritin release was observed and 3 
monitored by HPLC (Figure 3C). Therefore, in these conditions, PLA fibres act as 4 
a protecting phase for icaritin loading. 5 
The versatility of this approach for the encapsulation of various drugs into UV 6 
crosslinked PTMC/PLA fibre composites was further demonstrated by replacing 7 
icaritin with Dexa. To investigate the occurrence of cross-reactions between 8 
methacrylate end-groups and Dexa, a PEG methacrylate was photo-cured in the 9 
presence of Dexa. The molar ratio of methacrylate: Dexa: PI was set at 10:1:1, 10 
comparing to that in PTMC composite where methacrylate: Dexa: PI was 10:0.15:1 11 
(for PTMC/PLA 1) and 10:0.5:1 (for PTMC/PLA 2), respectively. Higher Dexa 12 
concentration was used to increase signal intensity. The starting materials and 13 
resulting products were characterised via GPC. Dexa was identified by its RI signal, 14 
at 18.9 min (Figure 4A). The RI signal against elution time of Dexa and PEG-15 
methacrylate before and after UV curing is presented in Figure 4B. After UV 16 
curing, the intensity of Dexa peak (eluted at 18.9 min) is significantly reduced. In 17 
the meantime, the peak corresponding to PEG-methacrylate (17.9 min) is shifted 18 
to lower elution time (17.7 min) with increased signal intensity. The shift of PEG-19 
methacrylate signal peak, the decreased signal intensity of Dexa and the increased 20 
signal intensity of PEG-methacrylate constitute further evidence of the coupling 21 
between Dexa and PEG-methacrylate. The reaction between Dexa and 22 
methacrylate-ended macromers shows the instability of Dexa when exposed to 23 
UV-curing processes and its potential deactivation when directly integrated into 24 
20 
 
methacrylate-based matrices. It is therefore crucial to protect such drugs from 1 
exposure of radicals involved in the curing reaction.  2 
Therefore we proposed to use PLA electrospun fibers hot pressed into a PTMC 3 
matrix to protect Dexa loaded during photo-crosslinking, to ensure drug’s retention 4 
and release from the resulting scaffolds under its active form. SEM images of 5 
PTMC/PLA fiber composites are presented in Figure 5, where both sample surface 6 
and cross-sections are presented. The composite surfaces are covered by PTMC, 7 
with some PLA fibers exposed. We observed a good compatibility of the composite 8 
structures, as PLA fibers are well wetted by the PTMC matrix and interspaces 9 
between fibers are filled by the matrix and resulting in nearly void-free composites 10 
(Figure 5). Strong interfacial bonding of PLA fibres to PTMC is evidenced by SEM 11 
as most fibers remain well embedded within the matrix upon fracture of the 12 
corresponding samples, indicating good levels of interactions between fibers and 13 
the surrounding PTMC matrix. 14 
The mechanical properties of both electrospun fibers and PTMC/PLA fiber 15 
composites are quantified and the results are presented in Figure 6 and Table 1. It 16 
is found that the Young’s modulus and strength of electrospun fiber mats is much 17 
lower compared to bulk PLA (3.5 GPa, provided by supplier), although electrospun 18 
nanofibers (diameter 200-300 nm) were reported to exhibit Young’s moduli up to 19 
three times that of bulk PLA.43 The reason for this decrease is the combined effect 20 
of the porosity of the mats and the lack of orientation of the fibers, allowing fiber-21 
fiber sliding and reorientation during stretching of the mats. PLA 2 displays a 22 
higher Young’s modulus than PLA 0, presumably due to its higher crystallinity 23 
(5.7 % compared to 3.4 %). Meanwhile, PLA 1 exhibits lower failure strain, which 24 
21 
 
may be explained by its more heterogeneous structure, with the presence of beads 1 
in the nano-fibers (see Figure 1A, sample PLA1), which can act as potential defects, 2 
resulting in lower failure strains. However, the mechanical properties of PTMC 3 
were significantly improved by the addition of electrospun PLA fibers. The 4 
Young’s moduli of PTMC composites increased by more than one order of 5 
magnitude, compared to the simple PTMC matrix, and their tensile strength 6 
increased by 3-4 folds; This is an indication of the high reinforcing efficiency of 7 
the PLA fibers, as a result of the good integration of the electrospun fibers in the 8 
PTMC matrix. 9 
 10 
In vitro release of Dexa from electrospun fiber and PTMC/fiber 11 
composites 12 
The in vitro release profile of Dexa from electrospun fibers and PTMC/PLA fiber 13 
composites was examined next, over a period of five weeks, via HPLC analysis of 14 
the supernatant (Figure 7). All samples showed a quick decrease in their release 15 
rate in the first eight days followed by a stable and sustained release profile. PLA 16 
2 exhibited the fastest release rate over the whole test period compared to other 17 
samples (initially 1.1×10-6 M/day then decreases to 2.0×10-9 M/day after five 18 
weeks). By incorporating Dexa into PTMC composites, the elution kinetic is 19 
effectively reduced by 6-10 folds in the first four days. In comparison, a more 20 
stable Dexa release rate is achieved by incorporating PLA 2 into PTMC, for which 21 
release concentrations ranged from 1.4×10-7 M/day to 6.0×10-10 M/day. PLA 1 22 
fibers displayed the slowest initial release but a stable release profile, ranging from 23 
22 
 
4.1×10-9 M/day to 2.0×10-10 M/day. After integrating them within PTMC, the 1 
composites exhibited a faster initial release rate than fibers alone, in the first three 2 
days, but a stable release was maintained after ten days. The rapid initial Dexa 3 
release from composites is ascribed to the incomplete coverage of PTMC on the 4 
fiber surface (see Figure 3).  5 
For in vitro cell assays (four weeks period), PTMC/PLA fiber composites were 6 
used (both low and high Dexa loading (PTMC/PLA 1 and PTMC/PLA 2, compared 7 
to drug-free PTMC/PLA 0). According to the release kinetic results obtained 8 
(Figure 7), we can extrapolate that the concentrations of Dexa released in the 9 
culture media (using composite discs of 1.5 mg incubated in 200 µL cell culture 10 
medium) will range between 9.4×10-7 M to 6.5×10-9 M for PTMC/PLA 2 and 11 
6.4×10-7 M to 6.7×10-10 M for PTMC/PLA 1, which are in the bioactive 12 
concentration windows as previously mentioned.24 13 
In addition, after 5 weeks of incubation in PBS, the PTMC/PLA fiber composites 14 
were characterized using SEM (see supplementary information Figure SD1). These 15 
images clearly indicate that the composite structures were well preserved, with 16 
similar features to those initially observed on pristine composites (Figure 5), for 17 
both surface and cross-section analysis. We observed that the PLA fibers were still 18 
fully embedded within the PTMC matrix, indicating that the hybrid PTMC/PLA 19 
fiber structures are morphologically stable during the 5 weeks of experiment. 20 
 21 
 22 
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In vitro differentiation of MSCs triggered by Dexa release from composites 1 
Having confirmed the ability to release Dexa from PTMC/PLA composites, we 2 
next examined their potential to be used as carrier of Dexa and to maintain its 3 
bioactivity to trigger osteogenic differentiation of MSCs. To this aim, Dexa was 4 
selected as drug model has it exhibits a strong "concentration-dependent" 5 
biological activity on stem cells. For instance, depending on the charge of Dexa in 6 
medium, it can favour in vitro hBMSCs proliferation and/or osteogenic 7 
differentiation. Both et al, showed that cell culture medium supplemented with 10-8 
8 M of Dexa promoted both the proliferation and the differentiation of hBMSCs.44 9 
However, a reverse effect on hBMSCs has been reported using higher Dexa 10 
dosages (i.e. 10-7 M), with a shift toward adipogenic differentiation associated with 11 
a decrease cell proliferation rate44-46). Such biological activity makes Dexa an 12 
excellent candidate to validate the control of the release of Dexa enabled by 13 
PTMC/PLA hybrid systems.  14 
Two days post-seeding (Figure 8A), no difference in hBMSCs density could be 15 
detected between the different groups containing or not Dexa, either in the media 16 
or loaded in the films. Indeed, when cells were seeded at a low density of 6,000 17 
cells/well, a 3 to 5 days lag phase was usually observed, before a rapid growth 18 
phase is resumed.44 This corroborates our results as the effect of Dexa could be 19 
first seen at Day 6 (Figure 8B), with significant increase in cell proliferation for all 20 
groups containing Dexa. The effective release of Dexa from PTMC/PLA 1 and 2 21 
therefore correlates with an accelerated cell growth for those two groups in 22 
comparison to Dexa-free PTMC/PLA 0, in media depleted of any Dexa (OM-), 23 
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therefore confirming the retention of the activity of DM upon elution from 1 
PTMC/PLA scaffolds. Similar conclusions can be drawn for the later time points 2 
(Day 14, 21 and 28, Figure 8C, D and E respectively), with superior hBMSCs 3 
proliferation on OM+ condition, observed on both PTMC/PLA 0 and controls 4 
TCPS, and on PTMC/PLA loaded with Dexa (1 and 2) compared to PTMC/PLA 0 5 
even if not systematically significant. At day 21, fluorescence values for the 6 
PTMC/PLA 0 and TCPS groups cultivated in OM+ were similar to the PTMC/PLA 7 
1 and 2, demonstrating the beneficial effect of Dexa released from the composite 8 
films as no significance were observed between PTMC/PLA 0 and TCPS in OM+ 9 
compared to PTMC/PLA 1 and PTMC/PLA 2. As the cells reached high degrees 10 
of confluency following 21 days of cultivation, the fluorescent values measured at 11 
Day 28 were not increased compared to previous time-points, but results displayed 12 
similar trends (Figure 8E). For all time points, cell proliferation was always the 13 
lowest in BM conditions, in agreement with previous results, showing that ascorbic 14 
acid is an important stimulator of hBMSCs proliferation, in addition to Dexa.47 15 
Overall, our results demonstrated that the sustained release of biologically active 16 
Dexa from PTMC/PLA scaffolds stimulate hBMSCs proliferation, but without 17 
following a concentration-dependent scenario, as values for PTMC/PLA 1 were 18 
similar to PTMC/PLA 2 for all time points. Indeed, as shown by the release kinetic 19 
presented in Figure 7, the composite structures with the Dexa charges of 0.68 and 20 
2.42 wt% release the drug at a concentration below the cytotoxic threshold of 10-21 
7M.45,46  22 
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It is well known that supplementing media with the synthetic glucocorticoid Dexa 1 
at an appropriate dosage induces hBMSCs to differentiate towards osteogenic 2 
lineage. One early biochemical marker commonly investigated to validate 3 
osteogenic differentiation in vitro is alkaline phosphatase (ALP).48,49 For both time 4 
points investigated (Day 14 and 21, Figure 9A and B, respectively), the ALP 5 
activity was negligible on BM condition on both PTMC/PLA 0 and TCPS and on 6 
OM- without Dexa. Robust ALP stainings were observed in OM+ conditions, but 7 
also for cells growing on PTMC/PLA 1 and 2 substrates (Figure 9C, only shown 8 
for donor 1). Hence, the continuous release of Dexa from hybrid films allows to 9 
trigger stem cells differentiation, to a similar level to that observed for cells 10 
cultured in OM+, where media was constantly refreshed with 10 nM of Dexa, as 11 
no significant difference was measured between PTMC/PLA and TCPS in OM + 12 
and PTMC/PLA 1 and 2. 13 
ALP being an early osteogenic marker, it is not surprising to observe a decline of 14 
its activity between Day 14 and Day 21 for some groups (e.g. PTMC/PLA 2), 15 
revealing that the peak of ALP activity is already passed between those two time 16 
points. In fact, PTMC/PLA 2 releasing more Dexa than PTMC/PLA 1 (Figure 7), 17 
it is reasonable to hypothesize that the ALP peak occurred earlier in this condition 18 
and that, at Day 21, the ALP activity has already decreased again. Such 19 
phenomenon was reported in other studies, as during cell maturation ALP naturally 20 
decreases and cells start to deposit minerals (calcium and phosphate), considered 21 
as a later marker of osteogenic differentiation.50 In vitro mineralization was 22 
monitored in our study using Alizarin Red Staining (ARS) and quantification. 23 
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Further indication of osteogenic differentiation of hBMSCs induced by the release 1 
of Dexa was evidenced by the staining and quantification of calcium deposition 2 
(Figure 10). At both time points investigated (Day 21 and 28), the Dexa-depleted 3 
medium, present in the BM and drug-free Dexa PTMC/PLA 0 in OM- conditions, 4 
did not permit cells to mineralize their matrix (Figure 10B and C). In contrast, the 5 
presence of Dexa either directly supplemented within the medium (in OM+) or 6 
diffusing from PTMC/PLA 1 and 2 scaffolds allowed hBMSCs to fully undergo 7 
osteogenic differentiation with robust time-dependent biomineralization (Alizarin 8 
Red Staining images, Figure 10C). No significance was observed between Ca2+ 9 
formed in fully supplemented OM media and in the PTMC/PLA 1 and 2 for both 10 
time points. In this study, Dexa was selected as a driving source model for 11 
osteogenic differentiation. For the positive controls, this factor was directly 12 
introduced via the culture medium of hBMSCs (OM+).  13 
This osteogenic study therefore demonstrates that hybrid PLA/PTMC films loaded 14 
with Dexa successfully trigger hBMSCs differentiation towards a mature 15 
osteoblast lineage, as both early (ALP activity, Figure 9) and late (Ca2+ deposition, 16 
Figure 10) markers were up-regulated to similar levels to those observed for the 17 
positive OM+ condition. 18 
In addition, scanning electron microscopy (SEM) of samples obtained after 28 days of 19 
cell culture (Figure 11) corroborated ARS results. We could not detect any clusters of 20 
minerals deposited by the hBMSCs on the control groups (cells cultivated in the absence 21 
of Dexa, i.e. PTMC/PLA 0 in BM and in OM-), whereas numerous inorganic clusters 22 
(supposedly CaP) could be distinguished for the positive control (OM+) and on Dexa-23 
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loaded composite films (PTMC/PLA 1 and 2). Further EDX analyses confirmed the 1 
presence of Ca and P elements in the peri-cellular regions of hBMSCs cultivated on Dexa-2 
loaded film (Figure SD3). Therefore, SEM images confirm the potential of Dexa-loaded 3 
PTMC/PLA composite films to stimulate stem cells differentiation and to promote the 4 
deposition of minerals, essential for the application of these matrices in bone tissue 5 
engineering. 6 
 7 
Conclusion 8 
In this study, biocompatible and degradable polymeric composites based on 9 
electrospun PLA fibers and photo-crosslinked PTMC were successfully fabricated. 10 
The fibers were incorporated into PTMC macromer using a hot-pressing method 11 
followed by UV-curing. The composites exhibited significant improvements in 12 
mechanical performance compared to neat PTMC. The incorporation of PLA fibers 13 
permits to increase the PTMC’s Young’s modulus by one-order of magnitude and 14 
its tensile strength by 3-folds. The PLA fibers showed strong interfacial bonding 15 
with PTMC matrix (no fiber pull-out was observed for cold-fractured composites) 16 
and physical stability was observed, even after 5 weeks of in vitro incubation. 17 
Dexamethasone was loaded into composites by first co-electrospinning with PLA 18 
and then integration into the PTMC matrix. Using this approach, the UV-triggered 19 
cross-reaction between Dexa and methacrylate-terminated PTMC macromers was 20 
avoided. Thus the biological activity of Dexa integrated in such polymer-polymer 21 
composite structure was preserved. Moreover, the combination of electrospun 22 
28 
 
fibers with PTMC matrix also achieved a stable and sustained Dexa release profile, 1 
which allowed the improvement of hBMSCs proliferation and osteogenic 2 
differentiation. Overall, the concept of polymer/polymer hybrid structures offers a 3 
high degree of versatility as various therapeutics, especially those known to react 4 
with photo-crosslinking reaction, can be loaded in the corresponding scaffolds. 5 
This study demonstrates the potential of polymer-polymer scaffolds to 6 
simultaneously reinforce the mechanical properties of soft matrices and to load 7 
sensitive drugs in scaffolds that can be fabricated via additive manufacturing.  8 
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Figure 1: Loading Dexa in PLA results in homogenous and smooth PLA electrospun 4 
fibers. (A) SEM images of electrospun fibers; (B) fiber diameter distribution of PLA 0, 5 
PLA 1 and PLA 2. 6 
 7 
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 1 
Figure 2: PLA processing and drug loading influence the crystallinity of the electrospun 2 
nanofibers. DSC thermograms of the different PLA materials without Dexa (bulk PLA 3 
and PLA 0) and with Dexa loading (PLA 1 and 2) (A). Quantification of the PLA fibers 4 
thermal properties, depending on the processing method and presence of Dexa (B). 5 
 6 
 7 
 8 
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 1 
Figure 3: Representative chromatogram of (A) direct icaritin injection and (B) THF 2 
extractant of PTMC/icaritin-loaded fiber composite; (C) release profile of icaritin from 3 
electrospun fiber (black) and hot-pressed PTMC/PLA fiber composite (red). 4 
 5 
 6 
Figure 4: If unprotected, Dexa reacts with methacrylated macromere during UV-reaction. 7 
RI signal against elution time of Dexamethasone (A); RI signal against elution time of 8 
Dexa and PEG-methacrylate before (black) and after (red) UV curing (B). 9 
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Figure 5: PLA nanofibers exhibit a good physical interaction in hybrid PTMC/PLA 4 
structures. SEM images of (A) sample’s surface and (B) sample’s cross-section. 5 
 6 
 7 
 8 
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 1 
Figure 6: Incorporating PLA nanofibers into PTMC films dramatically improves 2 
materials mechanical resistance. Representative stress-strain curve of electrospun fiber 3 
mat and PTMC/PLA fiber composites 4 
 5 
 6 
 7 
Figure 7: Hybrid films are characterized by a sustained and prolonged release of Dexa. 8 
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Dexamethasone concentrations released daily from electrospun fibers and PTMC/PLA 1 
fiber composites (per 1.0 mg sample in 1.0 mL PBS at 37˚C, values presented are non-2 
cumulative). 3 
 4 
Figure 8: Dexa released from PTMC/PLA composite films impacts on hBMSCs 5 
proliferation. CellTiter Blue quantification of hBMSCs proliferating on the different 6 
substrates in various medium (BM, OM- and OM+) on day 2 (A), day 6 (B), day 14 (C), 7 
day 21 (D) and day 28 (E). £ reports significance for drug-free PTMC/PLA 0 regarding 8 
the nature of the medium, $ reports significance for drug-loaded PTMC/PLA on OM- 9 
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medium and ! reports significance for TCPS regarding the nature of the medium. ns 1 
reports non-significance. 2 
 3 
Figure 9: Dexa released from hybrid PTMC/PLA structures recreates in vitro similar 4 
condition than osteogenic media on hBMSCs ALP activity. ALP activity measured on day 5 
14 and day 21 (A and B respectively, £ reports significance for drug-free PTMC/PLA 0 6 
regarding the nature of the medium, $ reports significance for drug-loaded PTMC/PLA 7 
on OM- medium and ! reports significance for TCPS regarding the nature of the medium). 8 
ALP staining on hBMSCs monolayer cultivated on the diverse substrates (only shown for 9 
1 donor, but similar staining was obtained for both donor, C). 10 
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 1 
Figure 10: Dexa loaded PTMC/PLA film successfully triggers hBMSCs differentiation 2 
towards mineralizing osteoblast-cell lineage. Calcium deposition from hBMSCs was 3 
measured on day 21 and day 28 (A and B respectively, £ reports significance for drug-4 
free PTMC/PLA 0 regarding the nature of the medium, $ reports significance for drug-5 
loaded PTMC/PLA on OM- medium and ! reports significance for TCPS regarding the 6 
nature of the medium). Alizarin Red Staining of Ca2+ secreted by hBMSCs cultivated on 7 
the diverse substrates (only shown for 1 donor, but similar staining was obtained for both 8 
donor, C). 9 
 10 
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 1 
Figure 11: Biomineralization is visible on cell monolayers cultivated on Dexa-loaded 2 
films like in OM+ condition Illustration of PTMC/PLA composite film surface (dash lines 3 
denoted the cross-section and white triangle the PLA fibers). The red and white arrows 4 
denoted cells' membrane and clusters of minerals respectively. SEM were realized Day 5 
28 of the in vitro culture experiment. 6 
 7 
  8 
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Table 1: Results of the stress-strain test of electrospun fiber mats and PTMC/PLA fiber 1 
composites 2 
Sample 
Young’s 
modulus 
(MPa) 
Strength 
(MPa) 
Failure strain 
(%) 
PLA 0 45.32±5.45 2.31±0.94 50.42±27.23 
PLA 1 49.66±5.30 2.14±0.36 20.68±4.61 
PLA 2 65.89±21.98 2.18±0.82 72.34±6.85 
PTMC 2.73±0.48 1.31±0.43 62.17±11.42 
PTMC/PLA 1 30.92±6.80 4.61±1.19 106.85±9.78 
PTMC/PLA 2 33.96±19.33 3.86±1.41 81.97±13.17 
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